|
|
 |
 |
| |
 Printable version |
Budgeting novel anti-cancer drugs: with which resources? |
Bulletin du Cancer. Volume 87, Number 10, 745-54, Octobre 2000, Tribune libre
|
 Résumé
Article gratuit
|
Author(s) : Alain Livartowski, Philippe Beuzeboc, Béatrice Le Vu, Marinette Courbard, Jean-Yves Pierga, Jean-Marc Extra, Susy Scholl, Pierre Pouillart |
Summary : Recently developed drugs are ten to one hundred fold costlier than the chemotherapies of the past while the number of eligible patients and the average duration of treatments are ever increasing. The combined effect of these trends makes budgeting a daunting task, in particular for hospitals with budgetory allocation. Balancing budgets became difficult with the arrival of taxanes, but innovative therapies based on biotechnological advances will further increase the financial slide. Hospital running costs can not be infinitely reduced. Therefore, new rules that govern the financing of innovative therapies become mandatory and budgetary allocations based on DRG evaluations will no longer be feasible. |
Keywords : chemotherapy, drug expenditure. |
|
